CARISMA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.08 USD | -2.70% |
|
-18.80% | -63.14% |
Financials (USD)
| Sales 2024 * | 15.52M | Sales 2025 * | 7.2M | Capitalization | 44.87M |
|---|---|---|---|---|---|
| Net income 2024 * | -60M | Net income 2025 * | -73M | EV / Sales 2024 * | 2.89 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 6.23 x |
| P/E ratio 2024 * |
-0.86
x | P/E ratio 2025 * |
-0.87
x | Employees | 107 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.83% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -2.70% | ||
| 1 week | -18.80% | ||
| Current month | -18.80% | ||
| 1 month | -28.48% | ||
| 3 months | -52.00% | ||
| 6 months | -57.14% | ||
| Current year | -63.14% |
1 week
1.07
1.30
1 month
1.071.53
Current year
1.073.06
1 year
1.079.77
3 years
1.079.77
5 years
1.079.77
10 years
1.079.77
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 34 | 15-12-31 | |
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Richard Morris
DFI | Director of Finance/CFO | 51 | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Sanford Zweifach
CHM | Chairman | 68 | 21-10-31 |
| Director/Board Member | 66 | 22-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 32 M€ | +4.30% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 1.08 | -2.70% | 132,160 |
| 24-06-06 | 1.11 | -3.48% | 137,718 |
| 24-06-05 | 1.15 | -3.36% | 269,675 |
| 24-06-04 | 1.19 | -8.46% | 250,409 |
| 24-06-03 | 1.3 | -2.26% | 133,235 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotes
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Calendar
2024-06-13
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.08
USD
Average target price
7.6
USD
Spread / Average Target
+603.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -63.14% | 44.87M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +3.23% | 22.78B | |
| -10.44% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- CARM Stock
